ES3065434T3 - Methods of treating fabry patients having renal impairment - Google Patents

Methods of treating fabry patients having renal impairment

Info

Publication number
ES3065434T3
ES3065434T3 ES23219949T ES23219949T ES3065434T3 ES 3065434 T3 ES3065434 T3 ES 3065434T3 ES 23219949 T ES23219949 T ES 23219949T ES 23219949 T ES23219949 T ES 23219949T ES 3065434 T3 ES3065434 T3 ES 3065434T3
Authority
ES
Spain
Prior art keywords
methods
renal impairment
fabry patients
treating fabry
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES23219949T
Other languages
English (en)
Inventor
Jeff Castelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3065434(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of ES3065434T3 publication Critical patent/ES3065434T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES23219949T 2017-05-30 2018-05-30 Methods of treating fabry patients having renal impairment Active ES3065434T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762512458P 2017-05-30 2017-05-30
US201862626953P 2018-02-06 2018-02-06

Publications (1)

Publication Number Publication Date
ES3065434T3 true ES3065434T3 (en) 2026-05-06

Family

ID=65803261

Family Applications (5)

Application Number Title Priority Date Filing Date
ES22165669T Active ES3002433T3 (en) 2017-05-30 2018-05-30 Treating fabry patients having certain mutations
ES24164126T Active ES3052647T3 (en) 2017-05-30 2018-05-30 Methods of treating fabry patients having renal impairment
ES23219933T Active ES3065413T3 (en) 2017-05-30 2018-05-30 Methods of treating fabry patients having renal impairment
ES23219949T Active ES3065434T3 (en) 2017-05-30 2018-05-30 Methods of treating fabry patients having renal impairment
ES18733415T Active ES2970419T3 (es) 2017-05-30 2018-05-30 Migalastat para el tratamiento de pacientes de Fabry que tienen disfunción renal

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES22165669T Active ES3002433T3 (en) 2017-05-30 2018-05-30 Treating fabry patients having certain mutations
ES24164126T Active ES3052647T3 (en) 2017-05-30 2018-05-30 Methods of treating fabry patients having renal impairment
ES23219933T Active ES3065413T3 (en) 2017-05-30 2018-05-30 Methods of treating fabry patients having renal impairment

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18733415T Active ES2970419T3 (es) 2017-05-30 2018-05-30 Migalastat para el tratamiento de pacientes de Fabry que tienen disfunción renal

Country Status (14)

Country Link
EP (9) EP4245366A3 (es)
CN (4) CN117357524A (es)
DK (4) DK4327869T3 (es)
ES (5) ES3002433T3 (es)
FI (4) FI4327869T3 (es)
HR (4) HRP20240061T1 (es)
HU (2) HUE069837T2 (es)
LT (4) LT4324522T (es)
PL (4) PL3630114T3 (es)
PT (4) PT4324522T (es)
RS (4) RS65230B1 (es)
SI (2) SI4062916T1 (es)
SM (4) SMT202600114T1 (es)
TW (4) TW202322814A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021024886A2 (pt) * 2019-06-11 2022-01-25 Amicus Therapeutics Inc Métodos de tratar a doença de fabry em pacientes com insuficiência renal
WO2021026447A1 (en) * 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
JP2009537149A (ja) * 2006-05-16 2009-10-29 アミークス セラピューティックス インコーポレイテッド ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US20140219986A1 (en) * 2011-03-11 2014-08-07 Amicus Therapeutics ,Inc. Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
AU2017298376A1 (en) 2016-07-19 2019-03-07 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naive and ERT-experienced patients
KR20220116305A (ko) 2017-05-30 2022-08-22 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
WO2019017938A1 (en) * 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES

Also Published As

Publication number Publication date
FI4327869T3 (fi) 2026-03-09
LT4062916T (lt) 2025-01-10
TW202140000A (zh) 2021-11-01
EP4062916A1 (en) 2022-09-28
HRP20260346T1 (hr) 2026-04-24
FI4324522T3 (fi) 2026-03-09
FI3630114T3 (fi) 2024-01-30
RS67849B1 (sr) 2026-03-31
EP4327869A3 (en) 2024-05-22
EP4245366A9 (en) 2023-12-06
TWI775453B (zh) 2022-08-21
PL3630114T3 (pl) 2024-03-25
TWI894750B (zh) 2025-08-21
CN111278438A (zh) 2020-06-12
EP4324522A3 (en) 2024-05-22
ES3052647T3 (en) 2026-01-12
HUE065615T2 (hu) 2024-06-28
RS66376B1 (sr) 2025-02-28
DK4062916T3 (da) 2025-01-13
EP3630114A1 (en) 2020-04-08
HRP20260335T1 (hr) 2026-04-10
DK3630114T3 (da) 2024-01-29
PT4062916T (pt) 2025-01-13
LT3630114T (lt) 2024-02-12
DK4324522T3 (da) 2026-03-16
ES2970419T3 (es) 2024-05-28
LT4327869T (lt) 2026-03-25
DK4327869T3 (da) 2026-03-16
PT4327869T (pt) 2026-03-12
PL4327869T3 (pl) 2026-04-27
TW202440104A (zh) 2024-10-16
RS67861B1 (sr) 2026-04-30
CN120732857A (zh) 2025-10-03
SMT202600114T1 (it) 2026-05-12
SMT202500016T1 (it) 2025-03-12
SMT202400037T1 (it) 2024-03-13
EP4327868A2 (en) 2024-02-28
FI4062916T3 (fi) 2025-01-10
ES3002433T3 (en) 2025-03-06
EP4324522B1 (en) 2025-12-10
HUE069837T2 (hu) 2025-04-28
TW202322814A (zh) 2023-06-16
CN117357524A (zh) 2024-01-09
SI4062916T1 (sl) 2025-04-30
PT4324522T (pt) 2026-03-13
EP4062916B1 (en) 2024-10-09
HRP20241738T1 (hr) 2025-02-28
EP4324522A2 (en) 2024-02-21
PL4062916T3 (pl) 2025-03-17
SMT202600113T1 (it) 2026-05-12
TWI795408B (zh) 2023-03-11
EP4635496A1 (en) 2025-10-22
ES3065413T3 (en) 2026-05-06
PL4324522T3 (pl) 2026-04-27
EP4245366A2 (en) 2023-09-20
EP3630114B9 (en) 2026-05-20
SI3630114T1 (sl) 2024-03-29
EP4374918A3 (en) 2024-08-14
EP4245366A3 (en) 2023-11-29
EP4327869B1 (en) 2025-12-10
EP3630114B1 (en) 2023-11-01
RS65230B1 (sr) 2024-03-29
PT3630114T (pt) 2024-02-01
EP4062915A1 (en) 2022-09-28
CN119587544A (zh) 2025-03-11
LT4324522T (lt) 2026-03-25
TW201900165A (zh) 2019-01-01
EP4374918B1 (en) 2025-07-16
EP4374918A2 (en) 2024-05-29
HRP20240061T1 (hr) 2024-03-29
EP4327869A2 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
GB2550825B (en) Implantable devices and related methods for heart failure monitoring
GB201804514D0 (en) Treatment of pyroptosis
GB201706406D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT PROCEDURES
ZA201705997B (en) Method of preventing or treating hearing loss
GB201815588D0 (en) Method of treatment
ZA201705847B (en) Treatment of pain
GB201804515D0 (en) Treatment of necroptosis
SG11202102878TA (en) Treatment methods
SG11202102827YA (en) Treatment methods
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
ES3065413T3 (en) Methods of treating fabry patients having renal impairment
GB201717555D0 (en) Blood filter
GB201801249D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment
GB201706642D0 (en) Method of treatment
GB201706452D0 (en) Method of treatment
GB201706398D0 (en) Method of treatment
GB201706404D0 (en) Method of treatment